Black Diamond Therapeutics, Inc. (BDTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q4 '24: 0 Q1 '25: 70M Q2 '25: 70M Q3 '25: 70M Q4 '25: 70M Q1 '26: 0 Q2 '26: 0 Q1 '19 Q3 '19 Q1 '20 Q3 '20 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '18: -8.9M Q1 '19: -11.1M Q2 '19: -16.2M Q3 '19: -22M Q4 '19: -29.3M Q1 '20: -38.4M Q2 '20: -46.4M Q3 '20: -56.7M Q4 '20: -69.6M Q1 '21: -87.4M Q2 '21: -107.1M Q3 '21: -124M Q4 '21: -126.9M Q1 '22: -121.8M Q2 '22: -110.3M Q3 '22: -97.1M Q4 '22: -92.8M Q1 '23: -88.7M Q2 '23: -85.6M Q3 '23: -87.5M Q4 '23: -86.5M Q1 '24: -85.1M Q2 '24: -87.2M Q3 '24: -81.4M Q4 '24: -78.8M Q1 '25: -4M Q2 '25: 4.7M Q3 '25: 11.9M Q4 '25: 12.5M Q1 '26: -53.3M Q2 '26: -51.9M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '18: -8.9M Q1 '19: -11.2M Q2 '19: -21.5M Q3 '19: -28.4M Q4 '19: -35.3M Q1 '20: -43.6M Q2 '20: -45.9M Q3 '20: -54.5M Q4 '20: -67.3M Q1 '21: -85.4M Q2 '21: -105.2M Q3 '21: -122.4M Q4 '21: -125.6M Q1 '22: -120.8M Q2 '22: -109.4M Q3 '22: -96M Q4 '22: -91.2M Q1 '23: -86.5M Q2 '23: -82.8M Q3 '23: -84.1M Q4 '23: -82.4M Q1 '24: -79.8M Q2 '24: -80.5M Q3 '24: -73.1M Q4 '24: -69.7M Q1 '25: 5.1M Q2 '25: 14.4M Q3 '25: 21.5M Q4 '25: 22.4M Q1 '26: -43.2M Q2 '26: -42.6M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q4 '19: -24.7M Q1 '20: -29.1M Q2 '20: -37.7M Q3 '20: -43.9M Q4 '20: -52.1M Q1 '21: -65.3M Q2 '21: -76.9M Q3 '21: -91.9M Q4 '21: -100.1M Q1 '22: -104.3M Q2 '22: -97.2M Q3 '22: -87.2M Q4 '22: -85.1M Q1 '23: -76.5M Q2 '23: -72.8M Q3 '23: -74.7M Q4 '23: -66.7M Q1 '24: -67.9M Q2 '24: -68.2M Q3 '24: -61.2M Q4 '24: -62.3M Q1 '25: 12.3M Q2 '25: 17.9M Q3 '25: 21.3M Q4 '25: 29.6M Q1 '26: -34M Q2 '26: -32.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q4 '19: -24.7M Q1 '20: -29.1M Q2 '20: -37.7M Q3 '20: -43.9M Q4 '20: -52.3M Q1 '21: -65.5M Q2 '21: -77.9M Q3 '21: -94.4M Q4 '21: -102.9M Q1 '22: -107M Q2 '22: -99.2M Q3 '22: -87.7M Q4 '22: -85.3M Q1 '23: -76.7M Q2 '23: -72.8M Q3 '23: -74.7M Q4 '23: -66.8M Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '20: 23.7M Q2 '20: 35.9M Q3 '20: 35.9M Q1 '21: 36.1M Q2 '21: 36.2M Q3 '21: 36.2M Q1 '22: 36.3M Q2 '22: 36.3M Q3 '22: 36.3M Q1 '23: 36.5M Q2 '23: 36.5M Q3 '23: 50.9M Q1 '24: 51.8M Q2 '24: 55.2M Q3 '24: 56.5M Q1 '25: 57.7M Q2 '25: 56.8M Q3 '25: 56.9M Q1 '26: 57.2M Q2 '26: 57.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '18: -4.42 Q1 '19: -5.49 Q2 '19: -10.53 Q3 '19: -13.87 Q4 '19: -16.99 Q1 '20: -15.63 Q2 '20: -10.05 Q3 '20: -6.05 Q4 '20: -2.05 Q1 '21: -2.38 Q2 '21: -2.92 Q3 '21: -3.39 Q4 '21: -3.47 Q1 '22: -3.33 Q2 '22: -3.01 Q3 '22: -2.64 Q4 '22: -2.52 Q1 '23: -2.39 Q2 '23: -2.28 Q3 '23: -2.13 Q4 '23: -1.88 Q1 '24: -1.66 Q2 '24: -1.50 Q3 '24: -1.33 Q4 '24: -1.27 Q1 '25: 0.06 Q2 '25: 0.23 Q3 '25: 0.36 Q4 '25: 0.39 Q1 '26: -0.75 Q2 '26: -0.73 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.